The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes

Journal of Vascular Research

Volumn 38, Issue 6, 2001, Pages 527-535

  Wilkinson Berka, Jennifer L ^a   Kelly, Darren J ^b   Gilbert, Richard E ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Angiotensin; Diabetes; Renin; Retinopathy; Vascular endothelial growth factor

Indexed keywords

GLUCOSE; VASCULOTROPIN;

CHRONIC DISEASE; DIABETIC NEUROPATHY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; REVIEW; STIMULUS RESPONSE; VISUAL IMPAIRMENT;

ANIMALS; DIABETIC RETINOPATHY; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; RENIN-ANGIOTENSIN SYSTEM; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035217155     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051088     Document Type: Review

References (102)

1. Update and implications from the Newcastle diabetic retinopathy study
2. Epidemiology of proliferative diabetic retinopathy
3. Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM complications study
4. Diabetic retinopathy. Pathogenesis and the role of retina derived growth factor in angiogenesis
5. Diabetic retinopathy
6. Ocular complications of diabetes mellitus
7. Analysis by immunocytochemistry and in situ hybridization of renin and its mRNA in kidney, testis, adrenal, and pituitary of the rat
8. The ovarian renin-angiotensin system A paracrine-intracrine regulator of ovarian function
9. Adrenaline cells of the rat adrenal cortex and medulla contain renin and prorenin
10. Potassium control of extrarenal renin secretion in transgenic (mRen-2)27 and normal rats
11. Renin in thymus, gut, hindlimb and adrenal of (mRen-2)27 and normal rats: Secretion and content studies
12. Angiotensin II and the heart: On the intracrine renin-angiotensin system
13. Renin-containing Müller cells of the retina display endocrine features
14. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: Evidence for an intraocular renin-angiotensin system
15. Renin, prorenin and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy
16. Angiotensin levels in the eye
17. Angiotensin II in the rabbit retina
18. Quantitative receptor autoradiographic analysis for angiotensin II receptors in bovine retinal microvessels: Quantitation with radioluminography
19. Expression and localization of angiotensin II type 1 receptor mRNA in rat ocular tissues
20. Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neuronal ocular tissues of the rat
21. Retinal neovascularization is prevented by blockade of the renin-angiotensin system
22. Differential contractile response of cultured microvascular pericytes to vasoactive agents
23. Glaucoma, capillaries and pericytes. 3. Peptide hormone binding and influence on pericytes
24. Use of an angiotensin-converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma
25. Intraocular pressure lowering effects of the renin inhibitor ABBOTT-64662 diacetate in animals
26. Contractile responses of cultured bovine retinal pericytes to angiotensin II
27. Angiotensin II induces c-fos expression in smooth muscle via transcriptional control
28. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II
29. Neovascularization produced by angiotensin II
30. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo
31. 2 receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation
32. Angiotensin-II-induced angiogenesis in sponge implants in mice
33. Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins-1 and -3 and angiotensin II in a rat sponge model
34. Antiangiogenic effect of KR31372 in rat sponge implant model
35. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure
36. Mechanisms of angiotensin-(1-7)-induced inhibition of angiogenesis
37. Renin-angiotensin system components and endothelial proteins as markers of diabetic microvascular disease
38. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications
39. A transmission and scanning electron microscopic study of surgically excised preretinal membrane proliferations in diabetes mellitus
40. Müller's cell involvement in proliferative diabetic retinopathy
41. Epiretinal membrane of proliferative diabetic retinopathy: An immunohistochemical study
42. The role of Müller cells in the formation of the blood-retinal barrier
43. Angiotensin II-like immunoreactivity in the retina of some mammalian species
44. Angiotensin-like immunoreactive cells in the chicken retina
45. Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells
46. Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations
47. Serum total renin is increased before microalbuminuria in diabetes
48. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat
49. Increased bradykinin and 'normal' angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats
50. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat
51. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes
52. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: A two-year trial
53. Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy
54. Ocular complications
55. Continued progression of retinopathy despite spontaneous recovery to normoglycemia in a long-term study of streptozotocin-induced diabetes in rats
56. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
57. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia
58. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization
59. Angiotensin II and retinal pericytes migration
60. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
61. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
62. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
63. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
64. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
65. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea
66. Vascular endothelial growth factor is a secreted angiogenic mitogen
67. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with non-proliferative diabetic retinopathy
68. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes
69. Upregulation of the vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat
70. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas
71. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor
72. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis
73. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro
74. Advanced glycation end products increase retinal vascular endothelial growth factor expression
75. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only
76. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways
77. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor
78. Modulation of VEGF production by pH and glucose in retinal Müller cells
79. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Müller cells
80. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats
81. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects
82. Protein kinase C: Structure, function, and regulation
83. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor
84. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
85. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells
86. Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells
87. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells
88. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells
89. Renin gene transfer restores angiogenesis and vascular endothelial growth factor expression in Dahl S rats
90. Angiotensin II potentiates endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells
91. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes
92. Angiotensin converting enzyme inhibition ameliorates retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes
93. Angiotensin II type 2 receptor mediates programmed cell death
94. Hyperoxia/normoxia-driven retinal angiogenesis in mice: A role for angiotensin II
95. Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians
96. A cohort study of the relationship of diabetic retinopathy to blood pressure
97. Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes in vitro
98. Pulsatile stretch stimulates vascular endothelial growth factor (VEGF) secretion by cultured rat cardiac myocytes
99. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells
100. Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro
101. Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: Potential mechanisms for exacerbation of diabetic retinopathy by hypertension
102. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38